Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Synthetic DNA Business Sold
July 12, 2004
| A version of this story appeared in
Volume 82, Issue 28
Dutch biotechnology company Qiagen has sold its synthetic DNA business to a management team for just under $25 million. The new company is backed by private investors; Qiagen will retain a 16% stake. The new company will be named Operon Biotechnologies, reflecting the name of the Operon Technologies business, based in Alameda, Calif., acquired by Qiagen in 2000. The buyout team is headed by Patrick A. Weiss, who founded Xeragon, acquired by Qiagen in 2002. His expertise is in nucleic acid chemistry and chemical synthesis operations.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X